Literature DB >> 9143697

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

T F Tedder1, J Tuscano, S Sato, J H Kehrl.   

Abstract

The development of B lymphocytes is a highly regulated process that depends in part on lineage-specific cell surface molecules. In addition, transmembrane signals generated through the B cell antigen receptor and other surface molecules regulate B cell responses to foreign antigens. Recent studies reveal CD22 to be a functionally significant receptor during these processes. CD22 is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 is a member of the Ig superfamily that serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. CD22 signaling is mediated via interactions with a number of kinases and phosphatases that bind the cytoplasmic domain through phosphorylated tyrosine residues located within consensus TAM and TIM motifs. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. Most notable in CD22-deficient mice is a significant diminution of surface Ig levels in these B cell subpopulations, which suggests that CD22 functions in vivo to adjust the signaling threshold of cell surface antigen receptors. A further understanding of CD22 function is required and may reveal roles for CD22 in disease susceptibility or the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143697     DOI: 10.1146/annurev.immunol.15.1.481

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  76 in total

1.  The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Authors:  Viola Biberacher; Thomas Decker; Madlen Oelsner; Michaela Wagner; Christian Bogner; Burkhard Schmidt; Robert J Kreitman; Christian Peschel; Ira Pastan; Christian Meyer Zum Büschenfelde; Ingo Ringshausen
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

Review 2.  Rethinking mechanisms of autoimmune pathogenesis.

Authors:  Shiv Pillai
Journal:  J Autoimmun       Date:  2013-06-25       Impact factor: 7.094

3.  Characterization of CD22 expression in acute lymphoblastic leukemia.

Authors:  Nirali N Shah; Maryalice Stetler Stevenson; Constance M Yuan; Kelly Richards; Cindy Delbrook; Robert J Kreitman; Ira Pastan; Alan S Wayne
Journal:  Pediatr Blood Cancer       Date:  2015-03-01       Impact factor: 3.167

4.  ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.

Authors:  Prabhjit K Grewal; Mark Boton; Kevin Ramirez; Brian E Collins; Akira Saito; Ryan S Green; Kazuaki Ohtsubo; Daniel Chui; Jamey D Marth
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Authors:  Xing Du; Richard Beers; David J Fitzgerald; Ira Pastan
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

6.  A reevaluation of CD22 expression in human lung cancer.

Authors:  Laurentiu M Pop; Stephen Barman; Chunli Shao; Jonathan C Poe; Guglielmo M Venturi; John M Shelton; Iliodora V Pop; David E Gerber; Luc Girard; Xiao-yun Liu; Carmen Behrens; Jaime Rodriguez-Canales; Hui Liu; Ignacio I Wistuba; James A Richardson; John D Minna; Thomas F Tedder; Ellen S Vitetta
Journal:  Cancer Res       Date:  2014-01-01       Impact factor: 12.701

7.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 9.  Biologic treatments for systemic rheumatic diseases.

Authors:  Y Shirota; G G Illei; N P Nikolov
Journal:  Oral Dis       Date:  2008-02-14       Impact factor: 3.511

10.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.